• admin@condrug.com
  • Mon - Sat: 8.00 am - 7.00 pm

We develop solutions for your clinical data needs

Linkedin-in Link
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Whatsapp

+1 (877) 703-6664

Free to Use
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Blog

Pharmacovigilance

AI-First Pharmacovigilance: How Machine Learning Is Redefining Drug Safety

Discover how an AI-first pharmacovigilance model transforms drug safety from a reactive cost center into a proactive, data-driven intelligence function. Learn the core machine learning building blocks—advanced NLP, graph-based learning, and probabilistic signal detection—that give life sciences companies a new competitive edge.

Protein-Peptide Drugs

What Makes Tirzepatide Different? Dual GIP/GLP‑1 Mechanism, Benefits & Clinical Outcomes

Discover how tirzepatide’s dual GIP and GLP‑1 receptor agonism sets it apart from traditional GLP‑1 drugs like semaglutide. Learn about its unique mechanism of action, powerful HbA1c reductions, double‑digit weight loss, and broad cardiometabolic benefits in type 2 diabetes and obesity.

New Drugs

Zavegepant Nasal Spray for Acute Migraine: How It Works, Benefits, and Clinical Evidence

Learn what zavegepant is, how this intranasal CGRP receptor antagonist differs from traditional triptans, and review key clinical trial evidence on its speed, effectiveness, and safety for acute migraine treatment.

Pharmacovigilance

AI-Powered Pharmacovigilance: How Intelligent Safety Systems Transform Drug Risk Detection

Discover how AI-powered pharmacovigilance is shifting drug safety from static reporting to real-time, intelligent signal detection. Learn how NLP and machine learning enhance case intake, multi-source surveillance, and regulatory reporting while preserving scientific rigor and patient trust.

Small Molecule Drugs
Structural illustration of KRAS protein highlighting the KRASG12C allosteric switch II pocket targeted by covalent small molecule inhibitors

From Undruggable to Drugged: KRASG12C Inhibitors and the Future of KRAS-Targeted Cancer Therapy

Discover how KRAS evolved from an “undruggable” oncogene to a validated drug target. Learn how covalent KRASG12C inhibitors like sotorasib and adagrasib work, and explore emerging noncovalent strategies for targeting other KRAS mutations in lung, colorectal, and pancreatic cancer.

Pharmacovigilance
Illustration of AI technology analyzing drug safety data and pharmacovigilance case reports in a healthcare setting

How AI Is Transforming Pharmacovigilance and Drug Safety Workflows

Discover how artificial intelligence is reshaping pharmacovigilance—from automated case intake and triage to advanced multi-source signal detection and social listening—helping drug safety teams move from reactive compliance to proactive risk management.

New Drugs

Casgevy Gene Therapy: How This CRISPR Breakthrough Treats Sickle Cell Disease and β-Thalassemia

Learn what Casgevy (exagamglogene autotemcel) is, how this CRISPR/Cas9-based gene therapy edits hematopoietic stem cells, reactivates fetal hemoglobin (HbF), and offers long-term relief for sickle cell disease and transfusion-dependent β-thalassemia.

Small Molecule Drugs
Illustration of AI-driven small molecule drug design showing molecular structures connected to neural network diagrams

AI-Designed Small Molecule Drugs: How Generative Models Are Transforming Discovery

Discover how AI-designed small molecule drugs are moving from hype to reality. Learn how generative models, graph neural networks, and reinforcement learning are reinventing medicinal chemistry and accelerating small molecule candidates into the clinic.

Pharmacovigilance
Illustration of AI-powered pharmacovigilance system analyzing real-world healthcare data for drug safety monitoring

How AI Is Transforming Pharmacovigilance: Real-World Drug Safety with Advanced Analytics

Discover how AI is revolutionizing pharmacovigilance by enabling continuous, real-world drug safety monitoring. Learn how EHRs, claims data, social media, and wearables power faster, smarter safety signal detection using NLP, machine learning, and advanced modeling.

Protein-Peptide Drugs

Why Tirzepatide Is Redefining Peptide Therapy for Type 2 Diabetes

Discover how tirzepatide’s dual GIP/GLP‑1 receptor agonism is transforming peptide therapy for type 2 diabetes, delivering unprecedented HbA1c reductions, significant weight loss, and broader metabolic benefits compared to traditional GLP‑1 drugs.

  • 1
  • 2
  • 3
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
Categories
  • New Drugs (53)
  • Pharmacovigilance (73)
  • Protein-Peptide Drugs (41)
  • Small Molecule Drugs (45)
Tags
adverse drug reactions adverse event detection AI in drug safety AI in Healthcare AI in Pharmacovigilance artificial intelligence deucravacitinib drug discovery Drug Safety GIP GIP GLP-1 dual agonist GLP-1 GLP-1 agonist healthcare AI healthcare data incretin therapy Life Sciences Machine Learning machine learning in healthcare machine learning in pharma] metabolic disease metabolic health migraine treatment NLP obesity treatment peptide therapeutics pharmacovigilance pharmacovigilance automation PROTACs real-world data] real-world evidence signal detection small molecule design small molecule drugs SURPASS trials targeted protein degradation tirzepatide TYK2 inhibitor type 2 diabetes type 2 diabetes treatment weight loss weight loss drugs weight loss medication [AI drug discovery [AI pharmacovigilance
Recent Posts
  • Gefapixant for Chronic Cough: How This P2X3 Antagonist Is Changing Treatment
    17/12/2025
  • What Is Retatrutide? Triple Agonist Weight Loss Drug Explained (GLP‑1, GIP, Glucagon)
    17/12/2025
  • Ensifentrine for COPD: Dual PDE3/4 Inhibitor Mechanism, Benefits & Clinical Data
    17/12/2025
  • Home
  • Workspace
  • Contacts

Copyright © 2026 ConDrug All Rights Reserved.

Linkedin-in Handshake